Communiqués Synlogic, Inc.

Actions

SYBX

US87166L2097

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 16:47:03 02/06/2026			Varia. 5j.	Varia. 1 janv.
0,7000 ^USD	+1,45 %		-4,50 %	-37,50 %

14/05	Synlogic, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
12/03	Synlogic, Inc. publie ses résultats annuels pour l’exercice clos le 31 décembre 2025	CI

Communiqués

23/12/24	Synlogic : Management Change/Compensation Form 8 K	PU
12/11/24	Synlogic : Reports Third Quarter 2024 Financial Results Form 8 K	PU
12/11/24	Synlogic Reports Third Quarter 2024 Financial Results	AQ
08/08/24	Synlogic Reports Second Quarter 2024 Financial Results	AQ
14/05/24	Synlogic Reports First Quarter 2024 Financial Results	AQ
14/05/24	Synlogic : Reports First Quarter 2024 Financial Results - Form 8-K	PU
19/03/24	Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results	AQ
20/02/24	Synlogic Adopts Limited Duration Stockholders Rights Plan	AQ
08/02/24	Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update	AQ
02/02/24	Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria	AQ
04/01/24	Synlogic Provides Corporate Update and Outlook for 2024	AQ
27/12/23	Synlogic Announces Contract with the Air Force Research Lab	AQ
19/12/23	Synlogic : Corporate Presentation, December 2023	PU
07/12/23	Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023	AQ
09/11/23	Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update	AQ
07/11/23	Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration	AQ
07/11/23	Synlogic : Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration - Form 8-K	PU
03/10/23	Synlogic Announces Closing of $21.0 Million Underwritten Public Offering	AQ
29/09/23	Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering	AQ
28/09/23	Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism	AQ
27/09/23	Synlogic Announces Reverse Stock Split	AQ
27/09/23	Synlogic Announces Reverse Stock Split	GL
21/09/23	Synlogic to Participate in Chardan’s Genetic Medicines Conference	AQ
19/09/23	Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100	AQ
10/08/23	Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update	AQ